Corium International Inc (NASDAQ:CORI) Director Robert Thomas sold 35,608 shares of the stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $8.86, for a total transaction of $315,486.88. Following the completion of the sale, the director now directly owns 35,608 shares of the company’s stock, valued at approximately $315,486.88. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of NASDAQ:CORI traded up $0.24 during mid-day trading on Friday, reaching $8.93. 241,600 shares of the company were exchanged, compared to its average volume of 265,950. The company has a debt-to-equity ratio of 1.89, a quick ratio of 7.95 and a current ratio of 8.11. The stock has a market capitalization of $313.50 million, a P/E ratio of -5.46 and a beta of 1.45. Corium International Inc has a 1 year low of $7.17 and a 1 year high of $13.93.

Corium International (NASDAQ:CORI) last posted its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.04. The firm had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $6.72 million. Corium International had a negative net margin of 155.21% and a negative return on equity of 298.48%. research analysts forecast that Corium International Inc will post -1.59 earnings per share for the current fiscal year.

Several analysts have recently weighed in on CORI shares. Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 price target on shares of Corium International in a research note on Friday, May 18th. ValuEngine cut shares of Corium International from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 17th. HC Wainwright set a $14.00 price target on shares of Corium International and gave the company a “buy” rating in a research note on Tuesday, May 15th. Zacks Investment Research raised shares of Corium International from a “sell” rating to a “hold” rating in a research note on Friday, May 11th. Finally, BidaskClub cut shares of Corium International from a “hold” rating to a “sell” rating in a research note on Wednesday, May 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $12.80.

Several large investors have recently bought and sold shares of the stock. RTW Investments LP boosted its position in shares of Corium International by 0.7% during the 2nd quarter. RTW Investments LP now owns 1,923,217 shares of the biopharmaceutical company’s stock worth $15,405,000 after purchasing an additional 12,695 shares during the period. BlackRock Inc. boosted its position in shares of Corium International by 17.8% during the 2nd quarter. BlackRock Inc. now owns 2,215,762 shares of the biopharmaceutical company’s stock worth $17,748,000 after purchasing an additional 335,257 shares during the period. Royce & Associates LP boosted its position in shares of Corium International by 99.2% during the 2nd quarter. Royce & Associates LP now owns 502,564 shares of the biopharmaceutical company’s stock worth $4,026,000 after purchasing an additional 250,300 shares during the period. Schwab Charles Investment Management Inc. boosted its position in shares of Corium International by 40.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 58,309 shares of the biopharmaceutical company’s stock worth $468,000 after purchasing an additional 16,900 shares during the period. Finally, Engineers Gate Manager LP purchased a new position in shares of Corium International during the 2nd quarter worth approximately $215,000. 95.26% of the stock is owned by hedge funds and other institutional investors.

About Corium International

Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.

Featured Story: Short Selling – Explanation For Shorting Stocks

Insider Buying and Selling by Quarter for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.